Amrutanjan Health Care Limited Overview
Amrutanjan Health Care is a 133-year-old Indian consumer-healthcare company whose eponymous yellow pain balm remains one of the most recognised OTC brands in South and East India. From that franchise it has built a small but diversified FMCG portfolio: topical pain relief (balms, roll-ons, sprays, gels), congestion care under "Relief", women's hygiene under "Comfy" (ranked fourth nationally in mass sanitary pads by management's account), rehydration drinks under "Electro+" and "Enerlyte", fruit beverages under "Fruitnik", and, since Q4 FY2026, razors and antiseptic plasters. FY2026 revenue was INR 502.55 Cr with PAT of INR 57.92 Cr. The company is debt-free with roughly INR 178–222 Cr of cash and liquid investments, and has just commissioned a INR 150 Cr sanitary-napkin plant to bring Comfy in-house. Its investment case turns on whether distribution expansion beyond southern and eastern strongholds and new-category margin repair can offset slowing pain-balm volumes and input-cost inflation.
What the company does. Amrutanjan manufactures, sources and markets branded consumer-healthcare and personal-care products sold through India's general trade, chemist, modern trade, e-commerce and quick-commerce channels. Its exchange profile describes the business as the manufacture, supply and sale of products in pain management, congestion management, beverages and hygiene, together with services in pain management. The company's FY2026 Annual Report (themed "Trusted Relief, Timeless Care") frames the portfolio around pain management, congestion management, women's hygiene and personal care, and beverages and rehydration, extending into adjacent personal-care categories, ortho pain and nasal care.
Business model. The model is that of an asset-light branded FMCG company that historically owned manufacturing for its core OTC products (two OTC units, in Kancheepuram District, Tamil Nadu, and Hyderabad) and its beverages (Tiruvallur District, Tamil Nadu), while outsourcing sanitary napkins to third-party converters. From June 2026 the women's hygiene business moved to in-house production at a new plant in Rangareddy District, Telangana. Value is created through brand equity, distribution reach and pricing power; competitive moats are brand recall in pain relief and a distribution network of 1,656 distributors reaching about 1.11 million outlets (as of 31 March 2025, per CARE Ratings).
Revenue model. Revenue is almost entirely product sales (well above 99%). A very small services line exists — the Advanced Pain Management Centre in Chennai providing non-surgical pain management, reported within "Others" (INR 2.77 Cr in FY2026, about 0.6% of revenue). There is no subscription or licensing revenue of note. Key SKUs of the pain balm franchise run on a cash-and-carry basis with distributors, which supports a short operating cycle (CARE: ~14 days in FY2026), while other products carry 15–45 days of credit.
Value-chain position. Amrutanjan sits at the brand-owner/manufacturer stage. It buys menthol, essential oils, paraffin waxes, polymers and packaging (upstream commodity exposure), converts or contracts conversion, and sells to distributors and stockists who service retailers. In women's hygiene it has now integrated backward into conversion. It does not own retail beyond a single brand store in Chennai (opened December 2021) and its e-commerce storefronts, including Amazon India and Amazon USA listings.
Customer types and end-markets. End consumers are mass-market Indian households, skewed to semi-urban and rural consumers in Tamil Nadu, Karnataka, Andhra Pradesh, Odisha, West Bengal and Assam; these six states accounted for roughly 60% of FY2026 revenue (CARE). Direct customers are distributors, stockists, chemists (the company added 44,000 directly serviced chemists in FY2026 and targets 100,000 by September of FY2027), modern trade, e-commerce marketplaces and quick-commerce platforms. Exports were ~2% of FY2026 revenue. End-markets served are OTC topical analgesics, cold and congestion remedies, sanitary napkins and adjacent feminine care, oral rehydration and electrolyte drinks, packaged fruit beverages, and (new) shaving and wound care.
Company's own description vs. independent characterisation. The company presents itself as a heritage Ayurvedic healthcare brand modernising into a diversified FMCG player. Independently, the business is best characterised as a high-margin, cash-generative pain-relief franchise (~60–65% of revenue) subsidising lower-margin diversification bets. Women's hygiene (~28% of revenue) has scaled successfully on the top line but has been margin-dilutive while outsourced; beverages (~6%) have been shrinking since regulatory changes in the ORS category. The company's consolidated EBIT margin of 12.3% in FY2026 (S&P basis) is well below its FY2022 peak of 19.7% and far below large peers such as Emami (EBITDA margin 25.5%), which reflects the drag of the diversification portfolio and elevated advertising.
Strategy
Stated strategy (FY2026 Annual Report and management commentary). Management articulates growth priorities around four themes: (1) distribution — widening reach in new markets while deepening penetration in strongholds through rural distribution and low-price packs; (2) brand building — sustaining the Amrutanjan franchise (yellow balm relaunch, "Har Dard Mitaye") and building Comfy; (3) portfolio expansion — new categories (razors, plasters, nasal care), extension of Comfy into "women's wellness", and relaunch of the Relief congestion brand in FY2027; and (4) people capabilities and digitisation — raising digitised processes from ~68–70% to 85% near-term, with an aspiration close to 100% of critical processes, through systems implementation. The long-term ambition, per CARE, is transformation into a diversified FMCG player.
Strategic initiatives in the last 24 months.
Medium-term guidance. Management expressed confidence in double-digit growth in revenue and operating profit for FY2027, supported by price increases, monetisation of the new Comfy plant, and the non-recurrence of one-time charges incurred in FY2026 (Q1 FY2027 investor presentation). No multi-year numerical targets (margin, ROE) were found. CARE's rating sensitivities provide an external frame: upgrade triggers include sustained scale above INR 1,000 Cr with healthy margins; downgrade triggers include operating income below INR 400 Cr or debt-funded capex lifting gearing above 0.5x.
Products & Services
Pricing is generally not disclosed by product in filings; the company emphasises low-price packs for rural penetration. "Launch year" is given where disclosed.
OTC — Pain Management (brand: Amrutanjan)
| Product | Description / capability | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Amrutanjan Pain Balm (Yellow; "Extra Power") | Flagship Ayurvedic menthol-camphor balm for headache, cold and body ache | Mass households, South & East India | 1893; relaunched 29 Nov 2025 with "Har Dard Mitaye" campaign | Core of the franchise; Q1 FY2027 pain-management volumes −3.4% |
| Amrutanjan Strong Pain Balm | Higher-strength balm variant | Users seeking stronger relief | — | Listed in FY2026 AR portfolio |
| Amrutanjan Maha Strong Pain Balm / New Maha Strong | Premium strength balm, reformulated "New" version | Body-ache sufferers | Not disclosed; "New" version recent | Exchange profile and AR |
| Amrutanjan Faster Relaxation Balm (White) | White balm variant for headache | Urban headache sufferers | FY2014-15 | Exchange profile |
| Headache Faster Relaxation Roll-on | Mess-free roll-on format; company describes itself as leader in roll-ons | Urban/working consumers | 10 ml SKU FY2014-15 | Q1 FY2025 presentation: AHCL leader in roll-on segment |
| Back Pain Roll-on (BPRO) / Advanced Back Pain+ Roll-on | Roll-on for back and muscular pain | Adults with back pain | — | Back-pain products cited as YTD FY2026 growth driver |
| Muscular Pain Spray / Joint Pain spray | Aerosol spray for muscle and joint pain | Sports / ortho pain | — | FY2026 AR timeline references extension to joint pain |
| Body Pain Cream; Amrutanjan Pain Cream Extra Power | Cream format "with Amrutanjan's unique aroma" | Body-ache sufferers | Extra Power promoted Q1 FY2025 | Sampling-driven launch |
| Body Pain Gel | Gel format | Body-ache sufferers | — | FY2026 AR |
| Stop Pain Dental Gel | Oral-care pain-relief gel | Toothache sufferers | 2,023 | Oral health care entry |
| "Stop" derma care range | Expansion into derma care | Skin-care consumers | Q1 FY2025 | Product specifics not disclosed |
OTC — Congestion Management (brand: Relief / Amrutanjan)
| Product | Description | Launch / status |
|---|---|---|
| Relief Cold Rub | Chest rub for cold and congestion | Long-standing; Relief brand to be relaunched in FY2027 |
| Relief Nasal Inhaler | Pocket inhaler | Long-standing |
| Relief Cough Syrup | Ayurvedic cough syrup | Long-standing |
| Relief Swas Mint | Mint lozenge for breathing comfort | Long-standing |
| Amrutanjan Maha Inhaler | Larger/stronger inhaler | Listed in FY2026 AR timeline |
| Nasal spray | Entry into nasal care | Q4 FY2026 |
Women's Hygiene & Personal Care (brands: Comfy, Smoothe)
| Product | Description | Launch / latest | Notes |
|---|---|---|---|
| Comfy Snug Fit (Regular) | Mass-segment sanitary napkin | FY2016-17 | Brand ranked 4th nationally in mass pads (management) |
| Comfy Snug Fit Regular Cottony | Cotton-feel variant | FY2022 | — |
| Comfy Snug Fit XL / Ultra XL | Larger sizes | — | XL grew 53% in Q1 FY2025 |
| Comfy Slim Fit | Thinner pad for urban consumers | Q1 FY2025, select markets | — |
| Comfy Night Pads | Overnight protection | FY2026 | Featured in Q3 FY2026 presentation |
| Comfy Period Pain Relief Roll-on | Topical roll-on for menstrual cramps | Not disclosed (marketed with TV media from FY2024) | Bridges pain and hygiene franchises |
| Comfy women's razors | Women's shaving | Q4 FY2026 | Razors: INR 3 Cr in Q1 FY2027; target INR 15 Cr p.a. |
| Smoothe men's razors | Men's shaving | Q4 FY2026 | New brand |
| Production | In-house from June 2026 at Telangana plant (700 M napkins p.a.) | — | Previously third-party |
Wound Care
| Product | Description | Launch | Notes |
|---|---|---|---|
| Amrutanjan Plastry | Antiseptic adhesive plasters | Q4 FY2026 | INR 1.12 Cr in Q1 FY2027; target INR 10 Cr p.a. |
Beverages & Rehydration (brands: Electro+, Enerlyte, Fruitnik)
| Product | Description | Launch / latest | Notes |
|---|---|---|---|
| Fruitnik Electro+ ORS / Amrutanjan Electro+ (WHO formula) | Electrolyte/ORS drink; WHO-formula variants | 2025 entries in AR timeline for Electro+ WHO | Repositioned after ORS regulatory changes |
| Amrutanjan Electro+ 160 ml | Smaller, lower-price pack | 2,025 | Affordability play |
| Enerlyte | ORS brand | — | Named by CARE as a key ORS brand |
| Fruitnik fruit juices and drinks | Packaged fruit-based beverages | Brand acquired 2011 | Manufactured in Tiruvallur District, TN |
Hydration drinks: INR 15.47 Cr net sales in Q4 FY2026; INR 8.04 Cr in Q1 FY2027 (+13.9%).
Services and Others
| Offering | Description |
|---|---|
| Amrutanjan Advanced Pain Management Centre / Pain Clinic, Chennai | Non-surgical pain management services; revenue INR 2.77 Cr in FY2026 |
| Legacy lines | Gripe water (alcohol-free), "Pep Pill" referenced in historical profiles |
Financial Narrative
Basis: standalone, Ind AS. Primary source FY2026 audited results (8 May 2026) and FY2025 Annual Report; line items standardised by S&P Global Market Intelligence. EBITDA defined as S&P operating income plus depreciation and amortisation (excludes other income). CARE's PBILDT (which adds back lease rentals) is shown separately.
Income Statement (INR Cr)
FY2026 additionally included exceptional items: profit before exceptional items and tax was INR 86.74 Cr (+25.5% YoY) versus reported PBT of INR 77.89 Cr, implying exceptional charges of ~INR 8.85 Cr (derived; FilingReader / company results, 9 May 2026). Management has described these as one-time charges that will not recur. CARE's PBILDT was INR 58.69 Cr (FY2025) and INR 75.69 Cr (FY2026), a PBILDT margin of 12.98% and 15.06% respectively.
Margins (%)
Growth rates (derived). Revenue CAGR FY2021–FY2026 (5-year, from FY2021 revenue of ~INR 332 Cr) ≈ 8.6%; FY2022–FY2026 (4-year) ≈ 5.5%; FY2023–FY2026 (3-year) ≈ 9.8%. PAT CAGR FY2021–FY2026 ≈ −1.1% (FY2021 PAT ~INR 61.2 Cr); FY2023–FY2026 ≈ 13.3%.
Commentary. The income statement tells a story of a pandemic-inflated peak followed by a reset and gradual recovery. FY2021–FY2022 benefited from abnormal demand for balms, inhalers and rehydration during Covid, producing an EBIT margin near 20%. FY2023 saw revenue fall 6.5% as pantry-loading reversed while costs (advertising, Comfy scale-up, input inflation) stayed elevated; PAT fell 40.7%. Since then revenue has compounded at roughly 10% a year with modest margin recovery: gross margin rebuilt from 48.5% (FY2024) to 51.4% (FY2026), helped by price-mix in pain management, while EBIT margin recovered only to 12.3% because of heavier brand investment and the margin drag from outsourced Comfy and a shrinking beverages unit. Other income (treasury yield on ~INR 200 Cr of liquid assets) contributes roughly 20–25% of PBT, which flatters reported profitability relative to operating performance. The Q1 FY2027 print — PAT INR 4.37 Cr versus INR 8.31 Cr, with PBT before exceptionals down to INR 8.10 Cr from INR 11.29 Cr and a INR 2.03 Cr exceptional provision related to lease-rent matters — signals renewed pressure from start-up costs at the new plant, input inflation (Middle East-linked crude and packaging costs) and weak pain-balm volumes.
Balance Sheet (INR Cr, as at 31 March)
Source: S&P Global Market Intelligence standardisation of annual reports FY2022–FY2025 and FY2026 audited results. CARE Ratings reports FY2026 net worth of INR 368.78 Cr and cash and bank balance of INR 221.85 Cr (INR 33 Cr cash plus ~INR 188 Cr bank deposits) — the difference from S&P reflects classification of deposits versus mutual-fund investments. Capital work-in-progress was INR 105.48 Cr at 31 March 2026 (company results), almost entirely the Telangana plant.
Commentary. The balance sheet is exceptionally conservative: no borrowings, lease liabilities under INR 2 Cr, and liquid assets equal to ~48% of equity at FY2026. The INR 130–150 Cr Comfy plant was funded entirely from internal accruals and liquid funds (CARE), which explains the decline in cash plus short-term investments from INR 207 Cr (FY2024) to INR 179 Cr (FY2026) and the near-tripling of PP&E. Working capital fell in FY2026 because "other current liabilities" jumped to ~INR 50 Cr (likely capex creditors and provisions). The FY2024 equity dip despite profit reflects the ~INR 35.5 Cr buyback.
Cash Flow (INR Cr)
Source: S&P Global Market Intelligence. Note that S&P's OCF deducts treasury income (~INR 15–17 Cr p.a.) as "other operating activities" and reclassifies it to investing, which depresses OCF/PAT; on CARE's basis gross cash accruals were INR 50–65 Cr annually over the last three years, with INR 64 Cr in FY2026.
Commentary. Cash conversion is adequate rather than outstanding. FY2026 FCF turned negative for the first time in the period because of plant capex (INR 55 Cr) and an INR 10 Cr inventory build ahead of the plant start. With the plant complete, capex should normalise to maintenance levels (historically INR 7–24 Cr) from FY2027, restoring positive FCF if operating profit holds.
Returns, Leverage and Efficiency Ratios (derived)
ROIC methodology: NOPAT (EBIT × 0.75) ÷ (equity + lease debt − cash, short-term and long-term investments), year-end. The extreme FY2022 figure reflects a tiny operating capital base; the decline to 31.5% in FY2026 is the arithmetic effect of the INR ~100 Cr plant entering invested capital before it earns. CARE reports interest coverage of 177.85x (FY2025) and 378.43x (FY2026) on a PBILDT basis, and an operating cycle of ~14 days in FY2026; the negative CCC above is sensitive to the inclusion of non-trade payables. TipRanks reports ROIC of 28.55% on a TTM basis (aggregator, date uncertain).
Commentary. Returns on equity of ~16–17% understate the core business's economics because one-half of the equity is parked in treasury assets earning 7–8%. Ex-cash, the franchise earns very high returns, but the incremental capital now committed to women's hygiene manufacturing will dilute ROIC until plant utilisation rises. The receivables trend (DSO up from ~32 to ~44–45 days since FY2023) reflects the growing share of chemist, modern trade and e-commerce channels with credit terms, as opposed to cash-and-carry balm distribution.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
OTC Products excl. Women's Hygiene (INR Cr) | 275.1 | 290.0 | 328.3 |
Women's Hygiene & Personal Care (INR Cr) | 105.3 | 124.0 | 139.9 |
Reported OTC Products segment total (INR Cr) | 380.4 | 414.0 | 468.2 |
Beverages (INR Cr) | 40.0 | 36.4 | 31.6 |
Others – Pain Management Centre (INR Cr) | 0.9 | 1.4 | 2.8 |
Total revenue from operations (INR Cr) | 421.2 | 451.8 | 502.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2022–FY2026)
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Beverages (INR Cr) | 31.9 | 32.5 | 40.0 | 36.4 | 31.6 |
Others (INR Cr) | 1.7 | 2.1 | 0.9 | 1.4 | 2.8 |
Segment Margins & Growth (%)
| Segment | FY2025 | FY2026 |
|---|---|---|
OTC excl. Women's Hygiene growth (%) | 5.4 | 13.2 |
Women's Hygiene & Personal Care growth (%) | 17.8 | 12.8 |
Beverages growth (%) | -8.9 | -13.4 |
Total revenue growth (%) | 7.3 | 11.2 |
Revenue by Segment (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
OTC excl. Women's Hygiene share (%) | 65.3 | 64.2 | 65.3 |
Women's Hygiene & Personal Care share (%) | 25.0 | 27.4 | 27.8 |
Beverages share (%) | 9.5 | 8.1 | 6.3 |
Others share (%) | 0.2 | 0.3 | 0.6 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBusiness Lines
| Line | Q1 FY2026 | Q1 FY2027 | YoY (%) |
|---|---|---|---|
Net sales (total) | 94.05 | 102.97 | 9.5 |
OTC Products net sales (as presented) | 56.97 | 57.26 | 0.5 |
Comfy / Women's Hygiene & Personal Care net sales | 28.61 | 33.80 | 18.1 |
Beverages net sales | 7.76 | 8.64 | 11.3 |
of which Hydration drinks | 7.06 | 8.04 | 13.9 |
Pain management volume growth (%) | 6.6 | -3.4 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 405.8 | 379.6 | 421.2 | 451.8 | 502.6 |
Revenue growth (%) | 21.9 | -6.5 | 11.0 | 7.3 | 11.2 |
Cost of goods sold (INR Cr) | 183.8 | 187.4 | 217.0 | 228.9 | 244.4 |
Gross profit (INR Cr) | 222.1 | 192.4 | 204.3 | 223.0 | 258.2 |
Operating income / EBIT (INR Cr) | 79.8 | 41.9 | 47.2 | 53.3 | 61.8 |
Depreciation & amortisation (INR Cr) | 3.8 | 5.2 | 6.1 | 6.5 | 6.3 |
EBITDA (INR Cr) | 83.6 | 47.1 | 53.3 | 59.8 | 68.1 |
Interest & investment income (INR Cr) | 11.2 | 11.8 | 14.8 | 16.0 | 17.6 |
Interest expense (INR Cr) | 0.5 | 0.1 | 0.2 | 0.2 | 0.2 |
Profit before tax (INR Cr) | 90.6 | 53.6 | 61.9 | 69.1 | 77.9 |
Tax (INR Cr, derived) | 23.4 | 13.8 | 17.0 | 18.3 | 20.0 |
Net income / PAT (INR Cr) | 67.2 | 39.8 | 45.0 | 50.8 | 57.9 |
EPS basic (INR) | 23.00 | 13.65 | 15.50 | 17.58 | 20.03 |
EPS diluted (INR) | 22.98 | 13.63 | 15.50 | 17.58 | 20.03 |
Weighted avg diluted shares (M) | 29.24 | 29.23 | 29.18 | 28.92 | 28.92 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 54.7 | 50.7 | 48.5 | 49.4 | 51.4 |
EBIT margin (%) | 19.7 | 11.0 | 11.2 | 11.8 | 12.3 |
EBITDA margin (%) | 20.6 | 12.4 | 12.7 | 13.2 | 13.5 |
Pre-tax margin (%) | 22.3 | 14.1 | 14.7 | 15.3 | 15.5 |
Net margin (%) | 16.6 | 10.5 | 10.7 | 11.2 | 11.5 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 349.9 | 362.1 | 366.9 | 421.4 | 508.9 |
Cash & equivalents (INR Cr) | 2.2 | 4.9 | 3.7 | 10.2 | 33.3 |
Short-term investments incl. trading securities (INR Cr) | 198.9 | 177.6 | 203.5 | 185.1 | 145.4 |
Cash + short-term investments (INR Cr) | 201.1 | 182.5 | 207.2 | 195.3 | 178.7 |
Long-term investments (INR Cr) | 22.3 | 42.7 | 11.8 | 41.7 | 46.2 |
Accounts receivable (INR Cr) | 38.3 | 33.0 | 47.9 | 55.8 | 60.6 |
Inventory (INR Cr) | 26.0 | 28.8 | 28.9 | 27.3 | 37.4 |
Total current assets (INR Cr) | 274.6 | 259.9 | 295.7 | 290.7 | 291.6 |
Property, plant & equipment incl. CWIP (INR Cr) | 43.5 | 47.5 | 49.5 | 63.9 | 155.3 |
Goodwill (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Other intangible assets (INR Cr) | 2.3 | 2.5 | 2.4 | 1.7 | 1.7 |
Accounts payable (INR Cr) | 60.4 | 47.4 | 55.9 | 69.0 | 70.9 |
Total current liabilities (INR Cr) | 77.5 | 63.0 | 69.9 | 84.6 | 126.2 |
Total debt – lease liabilities only (INR Cr) | 0.9 | 0.9 | 1.7 | 2.1 | 1.8 |
of which short-term (INR Cr) | 0.6 | 0.5 | 0.3 | 0.4 | 0.4 |
of which long-term (INR Cr) | 0.3 | 0.4 | 1.4 | 1.7 | 1.4 |
Net debt (negative = net cash) (INR Cr) | -200.2 | -181.6 | -205.4 | -193.2 | -177.0 |
Total liabilities (INR Cr) | 84.7 | 71.3 | 78.4 | 94.8 | 138.7 |
Shareholders' equity (INR Cr) | 265.1 | 290.8 | 288.5 | 326.6 | 370.2 |
Working capital (INR Cr) | 197.2 | 196.9 | 225.8 | 206.1 | 165.5 |
Book value per share (INR) | 90.70 | 99.48 | 99.79 | 112.97 | 128.04 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 52.2 | 20.2 | 27.9 | 50.9 | 36.0 |
Capital expenditure (INR Cr) | 23.5 | 8.9 | 6.7 | 35.6 | 55.0 |
Free cash flow (INR Cr) | 28.7 | 11.3 | 21.2 | 15.3 | -19.0 |
Dividends paid (INR Cr) | 12.5 | 14.4 | 13.4 | 13.3 | 13.2 |
Share buybacks (INR Cr) | 3.5 | 0 | 35.5 | 0 | 0 |
Investing cash flow (INR Cr) | -36.2 | -2.5 | 19.2 | -31.0 | -21.2 |
Financing cash flow (INR Cr) | -16.7 | -15.0 | -48.3 | -13.5 | -13.6 |
Cash taxes paid (INR Cr) | 24.2 | 16.1 | 16.5 | 17.9 | 19.0 |
OCF / PAT (%) | 77.7 | 50.8 | 62.0 | 100.2 | 62.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 27.9 | 14.3 | 15.5 | 16.5 | 16.6 |
ROA on average assets (%) | 21.5 | 11.2 | 12.3 | 12.9 | 12.4 |
ROIC on operating invested capital, year-end (%) | 140.6 | 47.2 | 49.7 | 43.6 | 31.5 |
Current ratio (x) | 3.54 | 4.12 | 4.23 | 3.44 | 2.31 |
Debt / equity (x) | 0.003 | 0.003 | 0.006 | 0.006 | 0.005 |
Net debt / EBITDA (x) | -2.39 | -3.86 | -3.85 | -3.23 | -2.60 |
Interest coverage, EBIT / interest (x) | 164.6 | 543.6 | 300.9 | 243.2 | 316.7 |
Asset turnover (x) | 1.30 | 1.07 | 1.16 | 1.15 | 1.08 |
Days sales outstanding (days) | 34.4 | 31.7 | 41.5 | 45.1 | 44.0 |
Days inventory outstanding (days) | 51.6 | 56.1 | 48.6 | 43.5 | 55.8 |
Days payables outstanding (days) | 119.9 | 92.3 | 94.0 | 110.0 | 105.9 |
Cash conversion cycle (days) | -33.9 | -4.5 | -3.9 | -21.4 | -6.1 |
Geography Overview
| Geography | FY2026 share of revenue (%) | Source |
|---|---|---|
India – six core states (Tamil Nadu, Karnataka, Andhra Pradesh, Odisha, West Bengal, Assam) | ~60 | CARE Ratings, 31 Jul 2026 |
India – rest of country | ~38 (derived) | Derived |
Exports | ~2 | CARE Ratings |
Share Price & Returns
| Period | Return (%) | Source |
|---|---|---|
1 month to 5 Oct 2026 | 2.3 | Business Standard (BSE) |
3 months to 5 Oct 2026 | -3.5 | Business Standard (BSE) |
12 months to 5 Oct 2026 | -28.3 | Business Standard (BSE) |
3 years to 5 Oct 2026 | -16.4 | Business Standard (BSE) |
Valuation Multiples
| Multiple | Amrutanjan | Reference / peer context |
|---|---|---|
Market cap (INR Cr) | 1,485 | Kotak Neo, 16 Oct 2026 |
P/E TTM (x) | 27.5 | Kotak Neo 27.46; derived from TTM PAT ~INR 54.0 Cr (FY2026 PAT − Q1 FY2026 + Q1 FY2027) |
P/B (x) | 4.0 | Kotak Neo |
EV (INR Cr, derived) | 1,308 | Market cap less FY2026 net cash of INR 177 Cr |
EV / EBITDA FY2026 (x, derived) | 19.2 | EBITDA INR 68.1 Cr (S&P basis); 17.3x on CARE PBILDT |
EV / Sales FY2026 (x, derived) | 2.6 | Revenue INR 502.6 Cr |
Dividend yield (%) | ~0.95 | INR 4.90 FY2026 declared ÷ ~INR 514 |
Peer median P/E (x) | 34.3 | Value Research peer median, 8 Jun 2026 (Amrutanjan then at 27.7x, a ~19% discount) |
Peer median P/B (x) | 4.6 | Value Research, 8 Jun 2026 |
Valuation Multiples (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
P/E at FY-end (x) | 34.5 | 42.2 | 39.8 | 36.7 | 24.7 |
P/S at FY-end (x) | 5.72 | 4.43 | 4.25 | 4.13 | 2.85 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS – S&P paid-in-year basis (INR) | 4.6 | 4.6 | 4.6 | 4.6 | 3.9 |
Cash dividends paid (INR Cr) | 12.5 | 14.4 | 13.4 | 13.3 | 13.2 |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
CARE Ratings | CARE A (issuer rating) | Stable | 31 Jul 2026 |
Moody's / S&P / Fitch | Not rated | — | — |
Analyst Conclusions
Management guidance. Double-digit revenue and operating-profit growth in FY2027, aided by price increases, Comfy plant monetisation, new categories (razors ~INR 15 Cr and Plastry ~INR 10 Cr annualised targets), the Relief relaunch and non-recurrence of FY2026 one-time charges; 100,000 direct chemists by September of FY2027; digitisation to 85% of processes.
Consensus expectations. No reliable sell-side consensus exists. For reference, achieving guidance from the FY2026 base implies FY2027 revenue above ~INR 553 Cr and EBIT above ~INR 68 Cr. Q1 FY2027 (revenue +9.5%, PAT −47%) leaves the profit guidance dependent on a strong H2.
Bull case.
-
Comfy margin inflection: with ~INR 140 Cr of revenue moving from outsourced to in-house production on high-speed lines, even a few hundred basis points of segment margin gain could add several crores to EBIT, while capacity of 700 M napkins p.a. supports growth and exports.
-
Distribution flywheel: going from ~56,000 to 100,000 direct chemists and pushing beyond the six states that generate ~60% of revenue gives a long runway for the core balm and roll-on franchise.
-
Valuation and balance-sheet support: at ~19x EV/EBITDA and ~27x P/E — below its own history (~37–42x) and below the peer median (~34x) — with ~12% of market cap in net cash and capex now complete, FCF should recover sharply in FY2027–FY2028.
Bear case.
-
Core franchise fatigue: pain-management volumes fell 3.4% in Q1 FY2027; if pricing is the main growth lever amid input inflation, volume erosion could accelerate against Emami, Reckitt and Sun.
-
Diversification destroys value: beverages shrank ~21% over two years; razors and plasters enter categories dominated by Gillette, Band-Aid and Hansaplast; the pad plant may run under-utilised, pushing ROIC down from 31.5% (FY2026) further.
-
Earnings quality and volatility: repeated exceptional charges (FY2026 ~INR 8.85 Cr; Q1 FY2027 INR 2.03 Cr), treasury income at ~23% of PBT, and negative FY2026 FCF undermine confidence; a sub-scale small cap with low institutional ownership may stay de-rated.
Key catalysts and monitorables (next 12 months).
Analyst verdict. Amrutanjan Health Care is a financially impregnable but strategically stretched heritage brand. Its core asset — a 133-year-old pain-balm franchise with dominant roll-on share and cash-and-carry economics — continues to produce steady cash and supports a debt-free balance sheet carrying roughly INR 180–220 Cr of liquidity. FY2026 was respectable: revenue grew 11.2% to INR 502.55 Cr, profit before exceptionals rose 25.5%, and the company completed a fully self-funded INR 150 Cr sanitary-napkin plant. CARE's newly assigned A/Stable rating fairly captures this credit strength. The equity story is more contested. Diversification has delivered top-line breadth but not profit breadth: women's hygiene scaled to ~28% of revenue while diluting margins under outsourcing; beverages have shrunk for two consecutive years; and the newest bets (razors, plasters, nasal sprays) target categories owned by global giants. Group EBITDA margins of ~13.5% sit roughly half of Emami's, and the Q1 FY2027 print — PAT down 47%, pain volumes negative, another exceptional charge — shows how thin the operating cushion is when input costs rise. The next three to four quarters are therefore decisive. If in-house Comfy production lifts hygiene margins, price increases hold without further volume loss, and the chemist expansion broadens the balm franchise beyond its six core states, earnings could compound in the mid-teens and the current ~27x P/E (a discount to both history and peers) would look undemanding, with net cash providing downside support. If not, the market's de-rating — shares down ~28% in a year — may prove justified, and capital locked in the new plant will depress returns. On balance, the risk-reward is neutral with a positive skew contingent on evidence: we would treat the Q2 and Q3 FY2027 results, specifically Comfy gross margins and pain-management volumes, as the gating signals before taking a constructive stance.
Prepared from public information as of 19 October 2026. Figures marked "derived" are analyst calculations from cited sources.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes |
|---|---|---|
S. Sambhu Prasad | Chairman & Managing Director | — |
N. Swaminathan | Chief Financial Officer | CFO; committee member since 12 Aug 2022 per governance filing |
Gagan Preet Singh | General Manager – Legal, Company Secretary & Compliance Officer | Signatory on 2026 filings |
M. Srinivasan | Former Company Secretary | Signatory on 2020 filings |
Board of Directors
| Name | Category | Notes |
|---|---|---|
S. Sambhu Prasad | Executive, Promoter, Chairman & MD | Combined Chair/CEO role |
Nagaraj Viswanathan (DIN 00190903) | Non-Executive Independent Director | Committee member from 12 Feb 2025 |
Muralidharan Swayambunathan | Non-Executive Independent Director | Reappointed for a five-year term (board approval c. Aug 2026; approved at 89th AGM, 23 Sep 2026) |
Ramaswami Krishnan | Non-Executive Independent Director | Newly appointed (c. Aug 2026) |
Raghavan Govindan | Former director | Retired at 88th AGM (23 Sep 2025); vacancy not filled |
Board & Management Changes
| Date | Change |
|---|---|
12 Feb 2025 | Nagaraj Viswanathan inducted to board committees |
23 Sep 2025 | Raghavan Govindan retires; shareholders decide not to fill vacancy |
23 Dec 2025 | Committee reconstitution |
c. Aug 2026 | Ramaswami Krishnan appointed Independent Director; Muralidharan Swayambunathan reappointed for five years; revised ESOP 2 phase approved (44 employees, 200,000 shares over FY2027–FY2031) |
Shareholding Trend
| Holder category | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
Promoters & promoter group (%) | 46.52 | 46.52 | 46.52 | 46.52 |
Foreign institutional investors (%) | 2.41 | 2.38 | 2.27 | 2.17 |
Mutual funds (%) | 7.55 | 7.55 | 7.55 | 7.02 |
Other domestic institutions (%) | 5.15 | 5.35 | 5.45 | 5.64 |
Retail and others (%) | 38.37 | 38.20 | 38.21 | 38.65 |
Major Shareholders
| Holder | Shares | Stake (%) | Category |
|---|---|---|---|
Goodhealth Holdings Private Limited | 5,825,803 | 20.15 | Promoter group |
Sambhuprasad Sivalenka (folio 1) | 2,990,730 | 10.34 | Promoter |
DSP Small Cap Fund | 1,415,225 | 4.90 | Mutual fund |
Ramaa Prabhakar Arikirevula (folio 1) | 1,371,530 | 4.74 | Promoter group |
Sambhu Prasad Sivalenka (folio 2) | 1,040,171 | 3.60 | Promoter |
Ramaa Prabhakar Arikirevula (folio 2) | 872,535 | 3.02 | Promoter group |
Carnelian Bharat Amritkaal Fund | 860,403 | 2.98 | AIF/institution |
Ramalingam Ganti | 730,640 | 2.53 | Promoter group |
Amulya Kamakshi Priya Arikirevula | 616,781 | 2.13 | Promoter group |
ICICI Prudential FMCG Fund | 610,223 | 2.11 | Mutual fund |
Dipak Kanayalal Shah | 324,036 | 1.12 | Public |
Carnelian Structural Shift Fund | 315,000 | 1.09 | AIF/institution |
Competitive Landscape
Competitors by Segment
| Segment | Competitor (brand) | Owner | Positioning vs Amrutanjan |
|---|---|---|---|
Pain balms | Zandu Balm, Mentho Plus | Emami Ltd | National leader in balms; far larger A&P budget |
Pain balms | Tiger Balm | Haw Par (Singapore) | Premium imported balm |
Topical analgesics (sprays/gels) | Volini | Sun Pharmaceutical Industries | Pharma-led sprays/gels; strong in chemist channel |
Topical analgesics | Moov | Reckitt | Strong in creams/sprays, urban |
Topical analgesics | Iodex | Haleon | Legacy balm/rub brand |
Congestion | Vicks VapoRub, Vicks Inhaler | Procter & Gamble Hygiene & Health Care | Category leader in rubs/inhalers |
Congestion / Ayurvedic | Dabur's healthcare range | Dabur India | Ayurvedic OTC breadth |
Sanitary napkins | Whisper | P&G Hygiene & Health Care | Market leader |
Sanitary napkins | Stayfree | Kenvue | Major national brand |
Sanitary napkins | Sofy | Unicharm India | Major national brand |
Sanitary napkins | Paree; D2C brands (e.g., Nua, Carmesi) | Soothe Healthcare; start-ups | Value and premium challengers |
ORS / electrolytes | Electral, Enerzal | FDC Ltd | Pharma ORS incumbents |
ORS / electrolytes | ORSL | Kenvue | Leading electrolyte drink |
Fruit beverages | Real | Dabur India | Juice leader |
Fruit beverages | Tropicana; Maaza | PepsiCo; Coca-Cola | Global majors |
Razors | Gillette | P&G | Dominant shaving brand |
Plasters | Band-Aid; Hansaplast | Kenvue; Beiersdorf | Category leaders |
Peer Comparison FY2026
| Metric | Amrutanjan | Emami | Dabur India | P&G Hygiene & Health Care |
|---|---|---|---|---|
Revenue (INR Cr) | 502.6 | 3,779.5 | 13,192.6 | 4,290.4 |
Revenue growth (%) | 11.2 | -0.8 | 5.0 | not comparable |
EBITDA / operating margin (%) | 13.5 | 25.5 | 18.6 | 23.2 |
PAT (INR Cr) | 57.9 | 775.3 | 1,868.7 | 856.5 |
PAT margin (%) | 11.5 | 20.5 | 14.2 | 20.0 |



